These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35048301)

  • 1. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
    Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
    J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
    Kalra S; Bhattacharya S; Kapoor N
    J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
    Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
    JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 9. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

  • 12. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
    J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.
    Mittman BG; Le P; Payne JY; Ayers G; Rothberg MB
    Curr Med Res Opin; 2024 Mar; 40(3):377-383. PubMed ID: 38193509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in adoption of new diabetic therapies with cardiovascular benefits.
    Vasti EC; Basina M; Calma J; Maron DJ; Rodriguez F; Sandhu AT
    Diabetes Res Clin Pract; 2023 Feb; 196():110233. PubMed ID: 36581144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.
    Whyte MB; Hinton W; McGovern A; van Vlymen J; Ferreira F; Calderara S; Mount J; Munro N; de Lusignan S
    PLoS Med; 2019 Oct; 16(10):e1002942. PubMed ID: 31589609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.